Find disease awareness content and relevant supporting materials

Indicated in the treatment of the following infections when caused by susceptible strains of the designated organisms: Acute bronchitis and acute exacerbations of chronic bronchitis caused by Streptococcus pneumoniae , Haemophilus influenzae (including beta-lactamase producing strains), Haemophilus parainfluenzae , Moraxella catarrhalis (including beta-lactamase producing strains) and Staphylococcus aureus . Pharyngitis and tonsillitis caused by Streptococcus pyogenes (group A streptococci). Pneumonia caused by S. pneumoniae , H. influenzae (including beta-lactamase producing strains) and M. catarrhalis (including beta-lactamase producing strains). Uncomplicated lower urinary tract infections , including cystitis and asymptomatic bacteriuria, caused by Escherichia coli , Klebsiella pneumoniae , Proteus mirabilis and Staphylococcus saprophyticus . Skin and skin structure infections caused by S. pyogenes (group A streptococci), S. aureus (including beta-lactamase producing strains) and Staphylococcus epidermidis (including beta- lactamase producing strains). Bacteriological studies, to determine the causative organism and its susceptibility to cefaclor, should be performed. Therapy may be started while awaiting the results of these studies. Once these results become available, antimicrobial therapy should be adjusted accordingly. Note: Cefaclor prolonged-release tablets are generally effective in the eradication of streptococci from the oropharynx. However, data establishing the efficacy of this antibiotic in the subsequent prevention of rheumatic fever are not available.

Distaclor is indicated for the treatment of the following infections due to susceptible micro- organisms: Respiratory tract infections, including pneumonia, bronchitis, exacerbations of chronic bronchitis, pharyngitis and tonsillitis, and as part of the management of sinusitis Otitis media Skin and soft tissue infections Urinary tract infections, including pyelonephritis and cystitis Distaclor has been found to be effective in both acute and chronic urinary tract infections. Cefaclor is generally effective in the eradication of streptococci from the nasopharynx, however, data establishing efficacy in the subsequent prevention of either rheumatic fever or bacterial endocarditis are not available.

Distaclor is indicated for the treatment of the following infections due to susceptible micro-organisms: Respiratory tract infections, including pneumonia, bronchitis, exacerbations of chronic bronchitis, pharyngitis and tonsillitis, and as part of the management of sinusitis Otitis media Skin and soft tissue infections Urinary tract infections, including pyelonephritis and cystitis Distaclor has been found to be effective in both acute and chronic urinary tract infections. Cefaclor is generally effective in the eradication of streptococci from the nasopharynx, however, data establishing efficacy in the subsequent prevention of either rheumatic fever or bacterial endocarditis are not available.

Distaclor is indicated for the treatment of the following infections due to susceptible micro-organisms: Respiratory tract infections, including pneumonia, bronchitis, exacerbations of chronic bronchitis, pharyngitis and tonsillitis, and as part of the management of sinusitis Otitis media Skin and soft tissue infections Urinary tract infections, including pyelonephritis and cystitis. Distaclor has been found to be effective in both acute and chronic urinary tract infections. Cefaclor is generally effective in the eradication of streptococci from the nasopharynx, however, data establishing efficacy in the subsequent prevention of either rheumatic fever or bacterial endocarditis are not available.

1. For relief of the symptoms of flatulence, heartburn, dyspepsia and indigestion 2. As a laxative for relief of occasional constipation